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Abstract: The study aimed to verify the therapeutic action of isotretinoin in the treatment of sebaceous hyperpla-
sia. During two months, 20 patients with sebaceous hyperplasia took isotretinoin at a dosage of 1mg/kg per day.
Their skin lesions were counted and photographed before and after treatment and re-evaluated two years later.
The average number of sebaceous hyperplasia lesions before treatment was 24 per patient. At the end of two
months of therapy, the number of lesions decreased to 2 per patient. The statistically analyzed data showed a
reduction in the number of lesions following isotretinoin use (p < 0.05). Two years after the end of the treatment,
the average number of sebaceous hyperplasia lesions was 4 per patient. There were no severe side effects. Thus,
the data analysis suggests that isotretinoin is a safe and effective drug for treating the disease under study.
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INTRODUCTION
Sebaceous hyperplasia is generally treated
using surgical methods, including cauterizations and
excisions. However, depending on the number of
lesions and the cicatricial response of the skin, it may
be necessary to avoid such interventions.1
Alternatives, including lasers and other therapeutic
methods like photodynamic therapy, can be costly
and difficult to access.2,3
Drawing on literature reports about the use of
isotretinoin in isolated cases of sebaceous hyperplasia,
as well as studies that demonstrate histopathological-
ly the reduction of the sebaceous gland through use of
systemic isotretinoin, and by reviewng studies on the
sebo-supressive action of isotretinoin, we assumed the
drug’s effectiveness in treating sebaceous gland
hyperplasia.4-6
The use of isotretinoin in treating sebaceous
hyperplasia is justified by its effectiveness in reducing
the size of the sebaceous gland, in addition to its
action in diminishing the proliferation of basal sebo-
cytes, suppressing the production of sebum and
inhibiting the differentiation of the sebocytes in vivo.5
Several papers have studied the mechanism of
the retinoids’ anti-sebotropic effect. Some research
lines attempt to explain its sebo-supressive action by
studying the apoptosis of the sebocytes, while others
hold that the answer lies in the interaction of
isotretinoin in the metabolism of the androgens.7,8
Although the molecular base for the retinoids’
anti-sebotropic activity has not been explained entirely,
due to disagreement as to whether the mechanism
depends on nuclear receptors, many laboratory studies
of sebocytes and human sebaceous glands confirm the
effective action of isotretinoin in sebo-supression.6,9,11
However, our bibliographical review did not
identify any clinical essays performed with patients
whose sebaceous hyperplasia had been treated with
systemic isotretinoin.
Isotretinoin is known to be an inhibitor of the
size and function of sebaceous glands.10 As it has been
used for over two decades to treat acne, there exists
vast knowledge about its administration and, espe-
cially, its side effects.12
In the few papers identified that discuss its use
in sebaceous hyperplasia, isotretinoin was used in
low doses on a small number of patients, who were
generally monitored for only 2 months.4 This casts
doubt over the lesion recurrence rate after the end of
therapy mentioned in those studies.
In practice, it is known that decreasing the
dosage of isotretinoin in treating acne can provoke a
higher number of relapses, although some papers on
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dosage reduction to minimize side effects have report-
ed low recurrence.13
METHODS
In this clinical trial, therapy entailed a monthly
dosage similar to that normally used in acne treat-
ment, though for a shorter duration. The protocol
adopted was isotretinoin at a dosage of 1 mg/kg/day,
for two months).
Firstly, 20 patients were selected for the clinical
trial according to the following criteria:
Inclusion criteria: at least 18 years old, with
clinical and histopathological diagnosis of sebaceous
hyperplasia.
Exclusion criteria: under 18 years old, pregnant
women or women at childbearing age who do not
practice contraception, patients with dyslipidemia
and/or altered liver function.
However  , the number was decreased to 20
patients because some patients could not tolerate the
side effects of mucosa and skin dryness and subse-
quently abandoned the treatment or reduced drug
doses themselves. They were excluded from the
group; some were monitored in parallel to the study,
while others were lost during follow-up. Since results
were very similar in all the individuals examined,
there was no statistical requirement to increase the
number, as this would merely have repeated the pre-
viously obtained results.
All selected patients signed an informed con-
sent form, duly approved by the Research Ethics
Committee at  UNIFESP. There were no conflicts of
interest in the study.
Patients’ skin lesions were counted and pho-
tographed before and after treatment. They were
monitored for two years after the end of treatment in
order to evaluate the rate of recurring lesions and be
photographed again. Five patients did not return after
the two years for a recount of lesions. The side effects
of the drug were also evaluated. 
Changes in the number of lesions were exam-
ined,  comparing numbers at the beginning of
isotretinoin treatment and afterwards, using the
Wilcoxon signed-rank test for comparison, since a
decrease was observed in the number of lesions fol-
lowing use of the medication, in all patients (n=20). 
Variations were analyzed at two different
points: after two months and after two years of
isotretinoin treatment. In the two-year evaluation, we
worked with n=15, since five patients did not return
for monitoring. Throughout this assessment, we used
the Wilcoxon signed-rank test, as patients were
observed at three particular moments (the beginning
plus the two other analysis points), and because the
difference between the number of lesions at the
moments analyzed did not approach a normal distri-
bution (Gaussian). A confidence level of p<0.05 was
adopted.
We monitored patients for two years after the
end of treatment in order to assess the rates of recur-
ring lesions. 
RESULTS AND DISCUSSION
The period of isotretinoin use was effective as
regards the reduction in hyperplasia lesions, thus cor-
roborating the literature reviewed, in which sub-doses
of the medication were effectual at diminishing the
size of the sabeceous gland.13
Our study has shown that 100% of the patients
saw a significant decrease in the number of sebaceous
hyperplasia lesions in response to treatment.
Furthermore, note was taken of the fast therapeutic
action of systemic isotretinoin (Figures 1 to 6).
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FIGURE 1:
Before treat-
ment: 13 lesions
FIGURE 2:
Two months
after treament:
zero lesions
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The data analyzed demonstrated that, when
evaluating the patients at the three stages of the study
(before treatment, after two months of therapy and
two years without it), there was a reduction in the
average of 24 lesions (when monitoring first began) to
2 lesions (at two months of treatment). Importantly, all
patients experienced a reduction in the number of
lesions and even complete resolution in some cases.
When comparing results two years after the
end of treatment, we noted few recurring hyperplasia
lesions, with an average of 4 lesions. During the same
periods, the median number of lesions decreased from
22 (i.e. 50% of the patients had over 22 lesions, while
50% had under 22) to zero, following two months’
treatment. Equally, two years on from the end of med-
ication use, there was an increase from the median of
zero to three. This increase is statistically significant,
but is of little clinical importance to most patients,
since, despite recurrences in some patients, they still
invariably had fewer lesions two years later than they
did prior to initiating treatment (Table 1).
213 Tagliolatto S, Santos Neto OO, Alchorne MMA, Enokihara MY 
FIGURE 3:
Two years after
treatment: 3
lesions
FIGURE 6:
Two years after
treatment: 4
lesions
FIGURE 4:
Before treat-
ment: 18 lesions
FIGURE 5:
Two months
after treament:
zero lesions.
Stage of Treatment Average Median Standard Test *
Deviation
Beginning 24 22 16 p<0.05
After the treatment 2 0 3
(2 months)
p=0.0001; n=20
TABLE 1: Comparison of the number of lesions at the three
stages of study
* Wilcoxon signed-rank test
Stage of Treatment Average Median Standard Test *
Deviation
Beginning 24 22 16 p<0.05
After the treatment 4 3 5
(2 years) 
p=0.0001; n=15
Stage of Treatment Average Median Standard Test *
Deviation
After the treatment 2 0 3 p<0.05
(2 months)
After the treatment 4 3 5
(2 years) 
p=0.0078; n=15
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NB.: There was evidence of a significant statis-
tical difference between the number of lesions at the
two moments evaluated.
Important note: One should remember that sta-
tistical significance must always be analyzed with ref-
erence to clinical significance. Potentially, there could
be evidence of statistical difference and yet this differ-
ence could still be clinically insignificant.
As regards side effects, use of a recognized
drug ensured safety for its administration. In particu-
lar, we observed dryness of the skin and mucosa,
which were expected, given our experience with its
use in acne therapy and the literature consulted about
the drug.5,14 During the short treatment with
isotretinoin, there was only one case where triglyc-
eride levels rose, which was addressed with monthly
serum dosages of circulating fats, leading to the return
to basal levels one month after the end of the protocol,
along with dietary reorientation.
Cosmetic improvement in skin through using
the medication, involving a reduction in blemishes
and softening of fine wrinkles, has been reported by
most patients, in line with our experience and the lit-
erature reviewed.15
Isotretinoin use at an age when pregnancy is no
longer a priority nor even possible in many cases,
minimized our concerns about the main side effect of
isotretinoin (teratogenicity), although countermea-
sures must always be taken.5,12,16
It was surprising to observe the maintenance of
the therapeutic result for two years after the end of the
treatment, with few recurring lesions. Given the short
length of treatment (two months), we expected a larg-
er number of lesions after that period, since recurrence
rates are reported to be around 19%, even in pro-
longed acne treatment.17
Although we obtained 100% effectiveness
regarding the decrease in lesions, it is important to
highlight that new studies are necessary for better
standardization of dosage and treatment length.
We propose new research protocols with the
aim of revealing the minimum dosage necessary for
hyperplasia resolution, as we believe that the dosage
of 1mg/kg/day for two months will not be necessary,
since, during treatment, patients already showed a
decrease in the number and size of lesions before com-
pleting the sixty days of proposed therapy. Some
patients, who were subsequently excluded from this
study, reduced the medication dosage themselves and
achieved similar results to those who followed the
protocol correctly.
Consequently, standardizing smaller doses pro-
motes isotretinoin use in sebaceous hyperplasia treat-
ment, due to the reduced costs and side effects, which
are, as seen in literature, dosage-dependent.5,14,18-20
CONCLUSION
Ultimately, we were able to confirm that sys-
temic isotretinoin use is an effective procedure in
treating cutaneous sabeceous hyperplasia. ❑
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